ranitidine (zantac) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Ranitidine, a histamine H2-receptor antagonist, is now well established as a potent inhibitor of gastric acid secretion effective in the treatment and prophylaxis of gastrointestinal lesions aggravated by gastric acid secretion.   NCATS

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Over the Counter
  • Delivery Methods: Oral, Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$0.0444 - $5.1820

Australia

$0.0469 - $6.6831
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

ah-19065 | albis | azanplus | azantac | dumoran | gavilast | gavilast-p | glaxosmithkline brand of ranitidine bismuth citrate | glaxo wellcome brand of ranitidine bismuth citrate | gr122311x | gr 122311x | gr-122311x | histac | pylorid | raciran 150 | raciran 300 | ran | raniberl | ranicalm | raniplex | ranitic | ranitidina | ranitidine | ranitidine bismuth citrate | ranitidine bismutrex | ranitidine hcl | ranitidine hydrochloride | ranitidinum | ranitidne | ranitil | rantec | rantidine | ranzac | tritec | vivatak | zaedoc 150 | zaedoc 300 | zantac | zantac 150 | zantac 25 | zantac 300 | zantac 75 | zantac 75 dissolve | zantac 75 relief | zantac 75 relief dissolve | zenetac

Organizations (121)

Research & Development (75)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (50)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (68)

Approved Indications (4)


 

Duodenal Ulcer (approved 1983)

Gastroesophageal Reflux (approved 1983)

Peptic Ulcer (approved 1983)

Zollinger-Ellison Syndrome (approved 1983)

Experimental Indications - Clinical Trial Phases 1-4 (66)


 

Anesthesia (Phase 4)

Aspirin (Phase 4)

Bacterial Infections (Phase 4)

Blood Protein Disorders (Phase 2)

Breast Neoplasms (Phase 2/Phase 3)

Carcinoma, Renal Cell (Phase 2)

Coronary Artery Disease (Phase 4)

Cough (Phase 3)

Critical Illness (Phase 4)

Diabetes Mellitus, Type 2 (Phase 1)

Drug Interactions (Phase 4)

Drug-Related Side Effects and Adverse Reactions (Phase 4)

Dyspepsia (Phase 4)

Esophageal Neoplasms (Phase 3)

Eustachian Tube (Phase 4)

Food-Drug Interactions (Phase 1)

Gastritis (Phase 4)

Gastroesophageal Reflux ()

Head and Neck Neoplasms (Phase 2)

Healthy Volunteers (Phase 1/Phase 2)

Heart Failure (Phase 1)

Helicobacter pylori (Phase 2/Phase 3)

Hematologic Diseases (Phase 2)

Hemodynamics (Phase 4)

HIV Infections (Phase 2)

Hodgkin Disease (Phase 1)

Hypertension (Phase 1)

Hypertension, Pulmonary (Phase 1)

Hypotension, Orthostatic (Phase 1)

Immune System Diseases (Phase 2)

Infections (Phase 2)

Intestinal Pseudo-Obstruction (Phase 4)

Job Syndrome (Phase 2)

Kidney Failure, Chronic (Phase 2)

Laryngopharyngeal Reflux (Phase 4)

Leukemia (Phase 1)

Leukemia, Hairy Cell (Phase 1)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)

Lymphoma, Large-Cell, Immunoblastic (Phase 2)

Mastocytosis, Systemic (Phase 1)

Multiple Myeloma (Phase 3)

Multiple Sclerosis (Phase 3)

Multiple Sclerosis, Relapsing-Remitting (Phase 4)

Nausea (Phase 4)

Neoplasms (Phase 4)

Neoplasms by Histologic Type (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Neoplastic Cells, Circulating (Phase 2)

Pain, Postoperative (Phase 4)

Pancreatic Neoplasms (Phase 4)

Paraproteinemias (Phase 2)

Peptic Ulcer ()

Pharmacokinetics (Phase 1)

Plasmacytoma (Phase 1)

Pneumonia, Ventilator-Associated (Phase 4)

Postpartum Hemorrhage (Phase 2)

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Prostatic Neoplasms (Phase 4)

Pulmonary Disease, Chronic Obstructive (Phase 1)

Pure Autonomic Failure (Phase 1)

Stomach Ulcer (Phase 3)

Thyroid Neoplasms (Phase 1)

Ulcer (Phase 4)

Vomiting (Phase 4)

Voriconazole (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 71
  • # of Trial Organizations: 75

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue